Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Pheon: advancing ADCs with first-in-class mAb, payload platform

Start-up banks $68M series A from Brandon, Forbion and Atlas; seeks to improve on a prior attempt to design new ADC payloads

By Paul Bonanos, Associate Editor
September 28, 2022 8:10 PM UTC

Months after CEO Bertrand Damour steered NBE to a sale to Boehringer Ingelheim, he has assumed leadership of Pheon, a start-up seeking to advance an antibody-drug conjugate as well as a payload technology platform the company hopes it can improve from a prior attempt.

Pheon Therapeutics Ltd. revealed a $68 million series A round on Wednesday, with Brandon Capital, Forbion and Atlas Venture as co-leaders. Seed investor Research Corporation Technologies (RCT) also participated...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Atlas Venture

Brandon Capital Partners Pty. Ltd.

Forbion